Royce & Associates’s Kindred Biosciences, Inc. KIN Stock Holding History

Royce & Associates’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-126,000	Closed	-$1.09M	–	1278
2018 Q1	$1.09M	Hold	126,000	–	–	0.01%	955
2017 Q4	$1.19M	Hold	126,000	–	–	0.01%	943
2017 Q3	$989K	Hold	126,000	–	–	0.01%	968
2017 Q2	$1.08M	Hold	126,000	–	–	0.01%	954
2017 Q1	$888K	Sell	126,000 -22,000	-15%	-$138K	0.01%	996
2016 Q4	$629K	Hold	148,000	–	–	﹤0.01%	990
2016 Q3	$736K	Hold	148,000	–	–	﹤0.01%	958
2016 Q2	$524K	Hold	148,000	–	–	﹤0.01%	983
2016 Q1	$511K	Buy	148,000 +58,000	+64%	+$205K	﹤0.01%	983
2015 Q4	$306K	Buy	+90,000	New	+$417K	﹤0.01%	1053

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

PVAM

Pacific View Asset Management San Francisco, California $20.8M AUM 20.08% 1-Year Est. Return

Royce & Associates's KIN Position: Q2 2018 in Review

Royce & Associates sold out of Kindred Biosciences, Inc. (KIN) in Q2 2018, closing a stake of 126,000 shares — an estimated $1.09M sold.

Royce & Associates first reported a position in KIN in Q4 2015 and held it in 10 quarters. The position peaked at $1.19M in Q4 2017. 73 funds tracked by Wall St. Rank hold KIN as of Q2 2018.

Royce & Associates reported no remaining Kindred Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
Royce & Associates sold 126,000 Kindred Biosciences, Inc. shares in Q2 2018, an estimated $1.09M.
Royce & Associates first reported a position in Kindred Biosciences, Inc. in Q4 2015 and held it in 10 quarters.
Royce & Associates's Kindred Biosciences, Inc. position peaked at $1.19M in Q4 2017.
73 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2018.

Based on Royce & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.